Ind-Swift Laboratories Ltd (ISLL) today posted 15.52% increase in its profit after tax at Rs 28.44 crore for the third quarter ended December 31, 2011 compared to the corresponding period last fiscal.
The company's profit after tax for the three months ended December 31, 2010 was Rs 24.62 crore, it said in a statement.
The firm's total revenue during the quarter under review increased 15.7% to Rs 358.80 crore as against Rs 310.11 crore in the third quarter of 2010-11.
Commenting on the results, ISLL Vice-Chairman N R Munjal said: "Our growth in profits is as per our expectations. Our growth plans for the last quarter of this year as well as over the next three-years are in place."
During the quarter the company's exports turnover was Rs 176.55 crore.
"The company got the KFDA (Korean FDA) approval and PMDA (Pharmaceutical and Medical Devices Agency Japan) approval this year and is supplying commercial quantities of its key molecules to USA and Japan," the company said.
ISLL makes active pharmaceutical ingredients and advanced intermediates.
Ind-Swift Laboratories scrips were trading at Rs 31.8 per share in te afternoon trade on the BSE, down 1.09% from the previous close.
